Show simple item record

dc.contributor.authorBattisti, NML
dc.contributor.authorBiganzoli, L
dc.date.accessioned2021-07-07T08:18:44Z
dc.date.available2021-07-07T08:18:44Z
dc.date.issued2021-11-01
dc.identifier.citationCurrent Opinion in Oncology, 2021, Publish Ahead of Print
dc.identifier.issn1040-8746
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4672
dc.identifier.doi10.1097/cco.0000000000000768
dc.description.abstractPURPOSE OF REVIEW: In this review, we describe the evidence on the efficacy and the safety of systemic treatments for the management of early breast cancer (EBC) in older individuals. RECENT FINDINGS: Chemotherapy has a temporary impact on quality of life (QoL) for older EBC patients and improves survival outcomes for those with oestrogen receptor (ER)-negative disease. Benefits were seen also in the context of comorbidities, although these may be influenced by selection bias. The Cancer and Aging Research Group-Breast Cancer tool can predict the risk of severe toxicities on chemotherapy in older patients. Gene expression profiling is less frequently used in older adults although it holds promise to better inform patient selection also in this age group.Postneoadjuvant systemic therapy and novel agents remain poorly described in older patients with EBC. No disease-free survival benefits were seen in older patients receiving abemaciclib plus adjuvant endocrine therapy. SUMMARY: Chemotherapy is beneficial for selected older patients with high-risk, ER-negative EBC. Although its impact on QoL is temporary, preferences, higher risk of toxicity and competing risks need to be carefully considered. Open questions remain on novel therapeutic approaches and gene expression profile in older EBC patients and more real-world evidence is warranted.
dc.languageeng
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.titleSystemic therapy for early breast cancer in older adults: current status and prospects.
dc.typeJournal Article
rioxxterms.versionAM
rioxxterms.versionofrecord10.1097/cco.0000000000000768
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2021-06-28
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCurrent Opinion in Oncology
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Breast Cancer Clinical Research
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Breast Cancer Clinical Research
pubs.publication-statusPublished
pubs.volumePublish Ahead of Print
pubs.embargo.termsNo embargo
icr.researchteamBreast Cancer Clinical Research
icr.researchteamBreast Cancer Clinical Research
dc.contributor.icrauthorBattisti, Nicolo


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record